Ting Wei, MD
Pain Medicine · Indianapolis, INNPI 1861999773
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,350 of the $5,324 with a category attached, or 62.9%. 29 manufacturers reported payments, led by Medtronic at 37.3% of the total. Reporting peaked in 2023 at $2,525 and has fallen 68.6% since, to $793 in 2025.
Across 94 payments — averaging $56.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Bioventus LLC$1K
- SPR Therapeutics, Inc$436
- Nevro Corp.$350
- Boston Scientific$116
- Avadel CNS Pharmaceuticals, LLC$116
- plus $1K from 23 others
What the payments were for
- Travel & lodging$1,97537%
- Food & beverage$3,35063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $1,988 |
| Bioventus LLC | 4 | $1,088 |
| SPR Therapeutics, Inc | 5 | $436 |
| Nevro Corp. | 7 | $350 |
| Boston Scientific | 1 | $116 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $116 |
| Averitas Pharma Inc. | 3 | $101 |
| Abbott | 2 | $100 |
| Painteq LLC | 5 | $92 |
| Vertex | 4 | $92 |
| UCB, Inc. | 4 | $86 |
| Jazz Pharmaceuticals Inc. | 3 | $82 |
| Azurity Pharmaceuticals, Inc. | 4 | $82 |
| Collegium Pharmaceutical, Inc. | 4 | $80 |
| Saluda Medical Americas, Inc. | 2 | $61 |
| Neurocrine Biosciences, Inc. | 2 | $57 |
| Si-bone, Inc. | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Vertos Medical, Inc. | 1 | $44 |
| AbbVie | 2 | $36 |
| SK Life Science, Inc. | 2 | $35 |
| Valinor Pharma, LLC | 2 | $31 |
| Lilly USA, LLC | 1 | $30 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Neurelis, Inc. | 1 | $21 |
| Globus Medical | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Pfizer | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$1,579
- Stimrouter Implantable Kit$1,058
- Senza$217
- SPRINT PNS System$135
- GENERAL PAIN MANAGEMENT$116
How this compares
$5,324 in reported general payments places this provider in the 65th percentile of 128 pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 606 | $18,511 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 561 | $15,583 |
| BelbucaBuprenorphine Hcl | 17 | $10,911 |
| Oxycodone Hcl | 163 | $4,279 |
| Pregabalin | 96 | $2,841 |
| Gabapentin | 138 | $1,733 |
| Tizanidine Hcl | 63 | $1,253 |
| Ketorolac Tromethamine | 59 | $646 |
| Morphine Sulfate ErMorphine Sulfate | 36 | $615 |
| Cyclobenzaprine Hcl | 45 | $593 |
| Tramadol Hcl | 62 | $577 |
| Morphine Sulfate | 14 | $462 |
| Methylprednisolone | 66 | $345 |
| Diclofenac Sodium | 21 | $336 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $80 | $10,91117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 128 pain medicine providers in Indiana.
Other pain medicine in Indianapolis
- John SwoffordIndianapolis$127K
- Philip ShumskyIndianapolis$27K
- Michael GoldbergIndianapolis$13K
- Thelma Green MackIndianapolis$11K
- Troy PfefferkornIndianapolis$8K
- Lori KieferIndianapolis$5K
- Raheleh Rahimi DarabadIndianapolis$5K
- Ahmed ElsahyIndianapolis$5K
- John KihlkenIndianapolis$4K
- Derron WilsonCarmel$616K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.